Skip to main content
European Commission logo
español español
CORDIS - Resultados de investigaciones de la UE
CORDIS
Contenido archivado el 2024-06-18

New approaches to analyze and exploit the human B and T cell response against viruses

Objetivo

Immunological memory confers long term protection against pathogens and is the basis of successful vaccination.
Following antigenic stimulation long lived plasma cells and memory B cells are maintained for a lifetime, conferring immediate protection and enhanced responsiveness to the eliciting antigen. However, in the case of variable pathogens such as influenza virus, B cell memory is only partially effective, depending on the extent of similarity between the preceding and the new viruses. The B cell response is dominated by serotype-specific antibodies and heterosubtypic antibodies capable of neutralizing several serotypes appear to be extremely rare.
Understanding the basis of broadly neutralizing antibody responses is a critical aspect for the development of more effective vaccines. In this project we will explore the specificity and dynamics of human antibody responses to influenza virus by using newly developed technological platforms to culture human B cells and plasma cells and to analyze the repertoire of human naïve and memory T cells. High throughput functional screenings, structural analysis and testing in animal models will provide a thorough characterization of the human immune response. The B cell and T cell analysis aims at understanding fundamental aspects of the immune response such as: the selection and diversification of memory B cells; the individual variability of the antibody response, the mechanisms of T-B cooperation and the consequences of the original antigenic sin and of aging on the immune response. This analysis will be complemented by a translational approach whereby broadly neutralizing human monoclonal antibodies will be developed and used: i) for passive vaccination against highly variable viruses; ii) for vaccine design through the identification and production of recombinant antigens to be used as effective vaccines; and iii) for active vaccination in order to facilitate T cell priming and jump start the immune responses.

Convocatoria de propuestas

ERC-2009-AdG
Consulte otros proyectos de esta convocatoria

Régimen de financiación

ERC-AG - ERC Advanced Grant

Institución de acogida

FONDAZIONE PER L'ISTITUTO DI RICERCA IN BIOMEDICINA
Aportación de la UE
€ 1 979 200,00
Dirección
VIA FRANCESCO CHIESA 5
6500 Bellinzona
Suiza

Ver en el mapa

Región
Schweiz/Suisse/Svizzera Ticino Ticino
Tipo de actividad
Research Organisations
Investigador principal
Antonio Lanzavecchia (Prof.)
Contacto administrativo
Gabriele Gendotti (Mr.)
Enlaces
Coste total
Sin datos

Beneficiarios (1)